Advertisement
Advertisement
-
TOPIC
 / company

BeOne

BeOne
The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement